Eli Lilly & Co. is paying $350 million upfront to collaborate with Chinese biotech Innovent Biologics Inc. in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers.
www.bloomberg.com
#Lilly #Inks #Deal #Innovent #Speed #Early #Drug #Development
Lilly Inks Deal with Innovent to Speed Up Early Drug Development
